Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Fate Therapeutics Inc    FATE

FATE THERAPEUTICS INC (FATE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Fate Therapeutics : and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2018 | 04:23pm CEST

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the Company has gained access to additional intellectual property from Memorial Sloan Kettering Cancer Center (MSK) that enables the development of gene-edited T-cell immunotherapies. The newly-licensed portfolio of intellectual property covers new chimeric antigen receptor (CAR) constructs as well as off-the-shelf CAR T cells, including the use of CRISPR and other innovative technologies for their production.

Fate Therapeutics is utilizing gene editing under its ongoing collaboration for the research and development of off-the-shelf CAR T-cell immunotherapies with Michel Sadelain, M.D., Ph.D., Director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at MSK. At the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Dr. Sadelain will present preclinical data on FT819, an off-the-shelf, TCR-less, CD19 CAR T-cell product manufactured from a clonal master induced pluripotent stem cell (iPSC) line.

"Engineering stem cells and using master iPSC lines for the renewable production of off-the-shelf CAR T cells has the potential to advance the cancer immunotherapy landscape," said Dr. Sadelain. "We are pleased with the breakthrough discoveries accomplished under our ongoing collaboration with Fate Therapeutics, and look forward to continuing our advancement together of off-the-shelf CAR T-cell products toward clinical development."

The use of clonal master iPSC lines can overcome the complexity, heterogeneity and substantial costs associated with using cells from a patient or an allogeneic donor. Instead, iPSC-derived T-cell immunotherapies can be consistently and repeatedly mass produced and delivered in an off-the-shelf manner, significantly reducing the cost of, and time to, patient treatment.

"The use of a gene-edited master iPSC line for the manufacture of off-the-shelf T-cell immunotherapies ensures complete removal of endogenous TCR expression, which is critical to avoid the life-threatening complication of graft-versus-host disease that is seen in allogeneic T-cell therapy," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. "The incorporation of these latest MSK technologies into our development of FT819 and our iPSC product platform advances our leadership position in developing off-the-shelf T-cell immunotherapies with improved safety, enhanced potency and expanded therapeutic reach."

Fate Therapeutics has exclusively licensed from MSK intellectual property covering the production and composition of iPSC-derived T cells for human therapeutic use. In addition, Fate Therapeutics owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

(c) 2018 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FATE THERAPEUTICS INC
05/18FATE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Regulation F..
AQ
05/17FATE THERAPEUTICS : and Memorial Sloan Kettering Cancer Center Expand Scope of L..
AQ
05/17FATE THERAPEUTICS : Reports First Quarter 2018 Financial Results and Highlights ..
AQ
05/17FATE THERAPEUTICS : and Memorial Sloan Kettering Cancer Center Expand Scope of L..
AQ
05/16Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of ..
GL
05/10FATE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
05/10FATE THERAPEUTICS : 1Q Earnings Snapshot
AQ
05/10FATE THERAPEUTICS INC : Results of Operations and Financial Condition, Financial..
AQ
05/10Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights..
GL
05/10FATE THERAPEUTICS : to Webcast Conference Call Reporting First Quarter 2018 Fina..
AQ
More news
News from SeekingAlpha
05/14HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/14/2018) 
05/10Fate Therapeutics' (FATE) CEO Scott Wolchko on Q1 2018 Results - Earnings Cal.. 
05/10Fate Therapeutics misses by $0.05, misses on revenue 
05/09Notable earnings after Thursday?s close 
05/04Fate Therapeutics files for $150M mixed shelf offering 
Financials ($)
Sales 2018 4,25 M
EBIT 2018 -59,1 M
Net income 2018 -59,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 144x
Capi. / Sales 2019 266x
Capitalization 611 M
Chart FATE THERAPEUTICS INC
Duration : Period :
Fate Therapeutics Inc Technical Analysis Chart | FATE | US31189P1021 | 4-Traders
Technical analysis trends FATE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,8 $
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
J. Scott Wolchko President, Chief Executive Officer & Director
William H. Rastetter Chairman
Daniel D. Shoemaker Chief Scientific Officer
Chris M. Storgard Chief Medical Officer
Amir H. Nashat Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FATE THERAPEUTICS INC84.45%611
GILEAD SCIENCES-5.60%88 639
VERTEX PHARMACEUTICALS4.75%40 003
REGENERON PHARMACEUTICALS-21.45%31 288
GENMAB19.78%11 817
BEIGENE LTD (ADR)97.99%10 337